Sign In
Buy VIVO
$5.74
-0.620 (-9.75%)
At Close: Jun 03, 2026
Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates
02:15pm, Friday, 04'th Feb 2022 Zacks Investment Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience, Inc.'s (VIVO) CEO Jack Kenny on Q1 2022 Results - Earnings Call Transcript
02:03pm, Friday, 04'th Feb 2022
Meridian Bioscience, Inc.'s (VIVO) CEO Jack Kenny on Q1 2022 Results - Earnings Call Transcript
Why Meridian Bioscience's Shares Are Rising Today?
11:30am, Friday, 04'th Feb 2022
Meridian Bioscience Inc VIVO has posted Q1 FY22 sales of $88.2 million, down 4.9% Y/Y, sharply beating the consensus of $70.29 million. Get the Inside Access Traders Are Using to Profit More and Win
Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates
10:43am, Friday, 04'th Feb 2022
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience Q1 2022 Earnings Preview
06:20pm, Thursday, 03'rd Feb 2022 Seeking Alpha
Meridian Bioscience (NASDAQ:VIVO) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open.The consensus EPS Estimate is $0.27 (-52.6% Y/Y) and the
GTS Sells SP5 Portfolio Company Comprising 2,115 Towers
10:59pm, Tuesday, 01'st Feb 2022 Kwhen Finance
Meridian awarded additional NIH funding to advance development of Revogene panel
05:12pm, Monday, 31'st Jan 2022 Seeking Alpha
Meridian Bioscience <> announced that the National Institute of Health ((NIH)) awarded an additional $2.5M worth of funding to accelerate the development of its Revogene
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
01:13pm, Monday, 31'st Jan 2022 Benzinga
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Johnson & Johnson (NYSE: JNJ) got the ball rolling on large-cap biopharma earnings, with
Earnings Preview: Meridian Bioscience (VIVO) Q1 Earnings Expected to Decline
08:00pm, Friday, 28'th Jan 2022 Zacks Investment Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Meridian Bioscience (VIVO) Q1 Earnings Expected to Decline
04:09pm, Friday, 28'th Jan 2022
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience launches saliva-specific mixes for DNA, RNA detection
03:19pm, Friday, 28'th Jan 2022 Seeking Alpha
Meridian Bioscience <> launched two master mixes that detect DNA and RNA in crude saliva samples.The company said the two new mixes, Lyo-Ready Direct DNA qPCR Saliva Mix…
Strategy Analytics: Apple iPhone Tops Global Smartphone Market in Q4 2021
03:14am, Friday, 28'th Jan 2022 Kwhen Finance
Meridian Bioscience names new chairman
07:15pm, Thursday, 27'th Jan 2022 Seeking Alpha
Meridian Bioscience <> elects John C. McIlwraith as new Board Chairman, effective Jan
Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022
03:05pm, Monday, 10'th Jan 2022 Business Insider Markets
CINCINNATI, Jan. 10, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report first quarter 2022 financial results Friday, February 4, 2022.
